Journal Title：Cell

Cell Press is a leading publisher of cutting-edge biomedical research and reviews. We drive science forward and promote cross-pollination of ideas with our passion for excellence and commitment to innovation. Our aim is to engage the scientific community by communicating important, exciting discoveries made today that will impact the future of research.

Our flagship journal, Cell, was launched by Benjamin Lewin in 1974 under the aegis of MIT Press. In 1986, Cell Press became established as an independent publisher and subsequently launched hallmark journals including Neuron, Immunity, and Molecular Cell. We joined the Elsevier family, our parent company, in 1998.

Today at Cell Press, our editorial and production teams collaborate with authors and reviews to publish 13 hallmark primary research journals, 3 primary research journals published on behalf of learned societies and 14 Trends review journals, including gold open access publications such as Cell Reports and Stem Cell Reports (on behalf of the ISSCR). We continue leading in the innovative presentation of exciting scientific discoveries, consistently focusing on delivering highly valued research that drives scientific discovery, spanning a wide range of biomedical disciplines.

Cell Press 是領(lǐng)先的尖端生物醫(yī)學(xué)研究和評論出版商。我們以對卓越的熱情和對創(chuàng)新的承諾推動科學(xué)進(jìn)步，促進(jìn)思想的交叉融合。我們的目標(biāo)是通過傳播當(dāng)今的重要、令人興奮的發(fā)現(xiàn)來吸引科學(xué)界，這些發(fā)現(xiàn)將影響未來的研究。

我們的旗艦期刊《Cell》由 Benjamin Lewin 于 1974 年在麻省理工學(xué)院出版社的支持下創(chuàng)辦。1986 年，Cell Press 成為一家獨立出版商，隨后創(chuàng)辦了包括《Neuron》、《Immunity》和《Molecular Cell》在內(nèi)的標(biāo)志性期刊。我們于 1998 年加入了母公司愛思唯爾家族。

如今在 Cell Press，我們的編輯和制作團(tuán)隊與作者和評論合作出版了 13 種標(biāo)志性主要研究期刊、3 種代表學(xué)術(shù)團(tuán)體出版的主要研究期刊和 14 種 Trends 評論期刊，包括黃金開放獲取出版物，例如《Cell Reports》和《Stem Cell Reports》（代表 ISSCR）。我們繼續(xù)在激動人心的科學(xué)發(fā)現(xiàn)的創(chuàng)新展示方面處于領(lǐng)先地位，始終專注于提供推動科學(xué)發(fā)現(xiàn)的高價值研究，涵蓋廣泛的生物醫(yī)學(xué)學(xué)科。

Cell創(chuàng)刊于1974年，由Cell Press出版商出版，收稿方向涵蓋生化與分子生物學(xué) - 生物全領(lǐng)域，在行業(yè)領(lǐng)域中學(xué)術(shù)影響力很大，屬于TOP期刊，國際一流期刊，關(guān)注度和專業(yè)度非常高，所以對原創(chuàng)文章要求創(chuàng)新性很高，過審難度很高，如果您有志于TOP期刊，建議關(guān)注此刊。平均審稿速度 約2月 ，影響因子指數(shù)45.5，該期刊近期沒有被列入國際期刊預(yù)警名單，廣大學(xué)者值得一試。